Ionis Pharmaceuticals, Inc. Forecast, price target & analysts
Ionis Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Ionis Pharmaceuticals, Inc. Classifications & Recommendation
Ionis Pharmaceuticals, Inc. Price Target
| Target Price | $91.80 |
| Price | $44.44 |
| Potential |
106.57%
register free of charge
|
| Number of Estimates | 25 |
|
25 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2027 .
The average Ionis Pharmaceuticals, Inc. target price is $91.80.
This is
106.57%
register free of charge
$120.75
171.71%
register free of charge
$60.60
36.36%
register free of charge
|
|
| A rating was issued by 32 analysts: 25 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2027 of
106.57%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 943.71 | 937.09 |
| 33.83% | 0.70% | |
| EBITDA Margin | -39.13% | -66.58% |
| 40.43% | 70.17% | |
| Net Margin | -40.41% | -64.07% |
| 37.22% | 58.53% |
28 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2026 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2026. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
27 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.38 | -3.62 |
| 21.71% | 52.10% | |
| P/E | negative | |
| EV/Sales | 7.73 |
27 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 15 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 15 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 08 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
